


Seeking Innovations to Improve Intratumoral CD8 T-Cell Dysfunction

Daiichi Sankyo, a global pharmaceutical company, is seeking **compounds and drug targets that restore CD8 T-cell function within solid tumors** to induce or maintain durable anti-tumor immunity.



Approaches of Interest:

- Compounds and novel drug targets that **prevent or reverse CD8 T-cell dysfunction**, such as exhaustion, in the tumor microenvironment to induce or maintain lasting anti-tumor responses
- Diseases of interest include **all solid tumor types**, and **all therapeutic modalities** are within scope
- **Existing, validated assay systems** for evaluating human CD8 T-cell dysfunction

Out of Scope:

- Hematological cancers
- Establishment of new assay systems

Developmental Stages of Interest:

- Opportunities from basic research through to Phase I are within scope
- Data from human-derived cells (e.g. PBMCs), *ex vivo* culture systems, or clinical specimens is of highest interest, although *in vivo* data will still be considered

Submission Information

Submission of one-page, **200–300-word briefs** is encouraged, along with any optional **supplementary information e.g. relevant publications**. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Opportunities sought

-  Technologies
-  Centres of excellence
-  Research projects
-  Company profiles
-  Biotech assets

Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **16th November 2026 - 11:59 pm GMT**

Have any questions?

Contact our team at campaigns@inpart.io